We developed a novel tumorigenicity model for these two cell lines comparatively, in the ache mutant embryos and healthy wild-type siblings in a microenvironment where ache, a marker for increased tumorigenicity and poor prognosis in human HCC, was depleted (Fig. 1). This evidence concerns the gene ACHE and hepatocellular carcinoma.